Iannone, Luigi Francesco
Fattori, Davide
Benemei, Silvia
Chiarugi, Alberto
Geppetti, Pierangelo
De Cesaris, Francesco
Article History
Accepted: 22 December 2021
First Online: 11 February 2022
Declarations
:
: Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.
: PG received personal fees from Allergan, Eli Lilly, Novartis, Amgen, and TEVA and grants from Amgen, TEVA, Eli-Lilly, Allergan, and Chiesi; was involved in the Scientific Advisory Board, Endosome Therapeutics; and is the founding scientist of FloNext srl, Spinoff of the University of Florence. FDC received personal fees from TEVA, Eli Lilly, and Novartis. LFI, DF, SB, and AC declare no conflicting interests.
: The data collected and analyzed for the current study are available from the corresponding author on reasonable request.
: The study was approved as a part of the <i>Registro Italiano Cefalee</i> (RICe) study by the local Ethics committee (Studio RICe, 14591_oss).
: Informed consent was obtained from every patient.
: Not applicable.
: Not applicable.
: PG, LFI, and FDC designed the study; LFI, DF, SB, AC, FDC, and PG performed the research; and LFI, PG, and FDC analyzed and interpreted the data. PG, DF, SB, AC, and FDC critically revised the draft manuscript. All authors critically reviewed the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.